Are antibodies directed against amyloid-β (Aβ) oligomers the last call for the Aβ hypothesis of Alzheimer's disease?
暂无分享，去创建一个
G. Logroscino | F. Panza | D. Seripa | A. Daniele | A. Greco | M. Lozupone | B. Imbimbo | Vittorio Dibello
[1] P. Tariot,et al. Randomized Trial of Verubecestat for Mild‐to‐Moderate Alzheimer's Disease , 2018, The New England journal of medicine.
[2] M. Mintun,et al. Trial of Solanezumab for Mild Dementia Due to Alzheimer's Disease , 2018, The New England journal of medicine.
[3] M. Andjelkovic,et al. A phase III randomized trial of gantenerumab in prodromal Alzheimer’s disease , 2017, Alzheimer's Research & Therapy.
[4] G. Logroscino,et al. Emerging drugs to reduce abnormal β-amyloid protein in Alzheimer’s disease patients , 2016, Expert opinion on emerging drugs.
[5] K. Rhodes,et al. The antibody aducanumab reduces Aβ plaques in Alzheimer’s disease , 2016, Nature.
[6] L. Lannfelt,et al. Safety and tolerability of BAN2401 - a clinical study in Alzheimer’s disease with a protofibril selective Aβ antibody , 2016, Alzheimer's Research & Therapy.
[7] T. Iwatsubo,et al. Aβ Immunotherapy: Intracerebral Sequestration of Aβ by an Anti-Aβ Monoclonal Antibody 266 with High Affinity to Soluble Aβ , 2009, The Journal of Neuroscience.
[8] D. Selkoe,et al. Orally available compound prevents deficits in memory caused by the Alzheimer amyloid‐β oligomers , 2006, Annals of neurology.
[9] H. Loetscher,et al. Gantenerumab: a novel human anti-Aβ antibody demonstrates sustained cerebral amyloid-β binding and elicits cell-mediated removal of human amyloid-β. , 2012, Journal of Alzheimer's disease : JAD.